Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Beijer Byggmaterial in connection with the acquisition of Kakeldax
Mandate

Vinge advises Beijer Byggmaterial in connection with the acquisition of Kakeldax

September 07, 2021 Employment and Benefits M&A Real Estate and Construction Corporate Commercial Intellectual Property

Vinge has advised Beijer Byggmaterial AB in connection with the acquisition of the Kakeldax group. The Kakeldax group consists of three strong brands – Stigs Kakel, Kakeldax and Kakelcentralen.

The group has more than 30 years of industry experience with 11 own stores, web shops and distributors across the country. The head office and central storage facility are located in Gothenburg.

Vinge’s team consisted of, among others, Jonas Bergström, Joacim Rydergård, Vilhelm Rondahl, Ellinor Wargenbrant and Beatrice Randow (M&A), Hedvig Ekdahl (Corporate Commercial), Frida Ställborn (Real Property/Lease Agreements), Lina Österberg (Environment), Karl-Hugo Engdahl (GDPR), Ebba Svenburg and Elin Broman (Employment Law), Felizia Wiker (IP) and Nathalie Hughes (VDR).

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025